

## Preliminary Programme

Paris, France  
5-7 November 2025

### Wednesday, 5 November 2025

**14:30-19:00** Lymphoma Working Party Scientific Business Meeting

### Thursday, 6 November 2025

**09:00-09:10** Welcome from the organizers

Ali Bazarbachi (LB)

**09:10-11:00** Session I: Aggressive lymphomas – DLBCL  
Chair: Bertram Glass (DE)

09:10-09:40 New classifiers: does it matter for treatment  
09:40-09:50 Discussion  
Case-based discussion third line and beyond (CART vs bispecifics):  
09:50-10:00 Junior, detailed case presentation  
10:00-10:30 Critical discussion of the presented case and state-of-the-art  
10:30-11:00 Is there still a role for autologous SCT in DLBCL Yes/No  
10:30-10:40 Yes  
10:40-10:50 No  
10:50-11:00 Discussion

Christian Gisselbrecht (FR)  
Bertram Glass (DE)

**11:00-11:30** Coffee break

**11:30-12:50** Session II: Mantle cell lymphoma  
Chairs: Morgane Cheminant (FR) & Peter Dreger (DE)

11:30-11:50 New classifiers: does it matter for treatment  
11:50-12:00 Junior presents a typical case of mantle cell lymphoma with several lines of treatment  
12:00-12:20 Discussion of the non-cellular therapy strategies  
12:20-12:40 Discussion of the cellular therapy options: transplant, CART-T and bi-specifics  
12:40-12:50 Discussion

Morgane Cheminant (FR)  
Clemence Loiseau (FR)  
Marco Ladetto (IT)  
Peter Dreger (DE)

**13:00-14:00** Lunch break

**14:00-15:20** Session III: Indolent B cell lymphoma  
Chair: Chara Kyriakou (UK) & Nour Moukalled (LB)

14:00-14:20 New classifiers in follicular lymphoma: does it matter for treatment  
14:20-14:30 Junior presents a typical case of follicular lymphoma with several lines of treatment  
14:30-14:50 Discussion of the non-cellular therapy strategies including bispecifics  
14:50-15:10 Discussion of the cellular therapy options: transplant, CART-T  
15:10-15:20 Discussion

Sandrine Roulland (FR)

Silvia Montoto (UK)

**15:30-16:50** Session IV: Peripheral T cell lymphoma  
Chair: Gandhi Damaj (FR) & Olivier Tournilhac (FR)

15:30-15:50 New classifiers in TFH: does it matter for treatment  
15:50-16:00 Case presentations selected among the submitted cases  
16:00-16:20 Standard treatment of the T-cell lymphoma with emphasis on allogeneic and autologous Transplantation + Q&A  
16:20-16:40 The pipeline of T cell engaging therapy for T cell lymphoma: where do we stand? + Q&A  
16:40-16:50 Discussion

François Lemonnier (FR)

Norbert Schmitz (DE)

Pier Luigi Zinzani (IT)

## Preliminary Programme

Paris, France  
5-7 November 2025

### Thursday, 6 November 2025 – continued

17:00-17:30 Coffee break

#### 17:30-18:20 **Session V: Cutaneous T cell lymphoma** **Chair: Alberto Mussetti (ES) & Eva Domingo (ES)**

17:30-17:40 Case presentations selected among the submitted cases  
17:40-18:10 CTCL: State-of-the-art treatment and role of cellular therapy  
18:10-18:20 Discussion

Eva Domingo (ES)

### Friday, 7 November 2025

#### 09:00-11:00 **Session VI: Hodgkin lymphoma first line** **Chair: Anna Sureda (ES) & Alina Tanase (RO)**

09:00-09:20 New classifiers in classical HL: does it matter for treatment  
09:20-09:30 Junior presents one case of NLPHL with multiple lines of therapy  
09:30-09:50 State-of-the-art treatment of NLPHL and role of cellular therapy  
09:50-10:00 Junior presents one case of classical HL, advanced stage  
10:00-10:30 Choices and options in the first line  
10:30-10:40 Discussion

Dennis Eichenauer (DE)

Anna Sureda (ES)

10:40-11:10 Coffee break

#### 11:10-12:30 **Session VII: Hodgkin lymphoma in relapse and difficult to treat cases** **Chair: Ali Bazarbachi (LB) & Luca Castagna (IT)**

11:10-11:20 Junior presents case of relapsed/refractory Hodgkin lymphoma  
11:20-11:50 Strategies at relapse  
11:50-12:00 A case of Hodgkin lymphoma with long-term complications  
12:00-12:15 Lung Cancer Screening in Hodgkin Lymphoma  
12:15-12:30 Survivors - a UK national initiative  
12:15-12:30 Discussion

Ali Bazarbachi (LB)

Kim Linton (UK)

12:30-13:30 Lunch break

#### 13:30-14:45 **Session VIII: Supportive care in cellular therapy** **Chairs: Anna Ossami Saidy (DE) & Rémy Duléry (US)**

13:30-13:50 Management of cytopenia after CART  
13:50-14:10 Neurological complications  
14:10-14:30 From CRS to HLH following CART  
14:30-14:45 Discussion

Martina Pennisi (IT)  
Roser Velasco (ES)

#### 14:45-16:00 **Session IX: Innovation in allotransplant** **Chair: Yasmina Serroukh (NL)**

14:45-15:05 Invariant NKT cells and risk of GVHD  
15:05-15:30 Artificial intelligence and multi-omics in allotransplant  
15:30-15:50 Methodology and bias in registry studies  
15:50-16:00 Discussion

Jacques-E. Galimard (FR)

#### 16:00-16:10 **Closing remarks**